Adelphi Trust’s AbbVie ABBV Stock Holding History

Adelphi Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.63M	Buy	10,464 +816	+8%	+$176K	1.75%	15
2026 Q1	$2.1M	Buy	9,648 +374	+4%	+$83K	1.71%	16
2025 Q4	$2.12M	Buy	+9,274	New	+$2.11M	1.73%	16

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Adelphi Trust's ABBV Position: Q2 2026 in Review

Adelphi Trust increased its AbbVie (ABBV) stake by 8.5% in Q2 2026, buying an estimated $176K and bringing the position to 10,464 shares worth $2.63M. The position accounts for 1.75% of the portfolio, ranked #15.

Adelphi Trust first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Adelphi Trust held 10,464 shares of AbbVie worth $2.63M as of Q2 2026.
Adelphi Trust bought 816 AbbVie shares in Q2 2026, an estimated $176K.
AbbVie made up 1.75% of Adelphi Trust's portfolio in Q2 2026, its #15 holding.
Adelphi Trust first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Adelphi Trust's 13F filing for Q2 2026, filed 1 Jul 2026.